Sanofi (SNY.US) globally pioneered the successful phase III study of OX40L monoclonal antibody.

On September 4, Sanofi (SNY.US) announced that the Phase III COAST 1 study of Amlitelimab for the treatment of atopic dermatitis achieved all primary and secondary endpoints. Amlitelimab is a fully human non-depleting monoclonal antibody targeting OX40L (OX40 ligand) developed by Sanofi. It can block the key immune regulatory factor OX40L from binding to its receptor OX40 and maintain a balance between pro-inflammatory T cells and regulatory T cells, thereby treating atopic dermatitis, asthma, hidradenitis suppurativa, and a series of other immune-mediated and inflammatory diseases. This drug is currently the only Phase III-stage OX40L antibody.